## Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)

Jan 04, 2018

**Source URL:** https://qa1.novartis.us/us-en/news/media-releases/novartis-drug-promacta-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa-0

## List of links present in page

1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-drug-promacta-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa-0